Ketamine and Dissociation: Why the Detached Feeling Is Monitored, Not Chased

One reason ketamine attracts so much attention is that the treatment experience can feel unusual. With esketamine, the FDA label states that common psychological effects include dissociative or perceptual changes, derealisation, depersonalisation, and distortions of time or space. These are not presented as incidental details. They are important enough that patients must be monitored for at least 2 hours after each treatment session, and the medication is available only through a REMS programme because of risks including sedation, dissociation, respiratory depression, and misuse.

That matters because dissociation is often romanticised in public discussion of ketamine. Clinically, it is handled much more cautiously. The treatment setting is designed around observation and containment, not around amplifying unusual states. The FDA label also says clinicians should carefully assess patients with psychosis before administration and only proceed if the benefit outweighs the risk. In other words, altered experience is recognised, but it is not treated as proof that the treatment is “working.”

That is consistent with more recent research. A 2024 review on personalising ketamine and esketamine treatment reported that the severity of treatment-emergent dissociative symptoms is typically not associated with antidepressant response. That is a useful corrective to the common assumption that a stronger dissociative experience means a stronger therapeutic effect. The evidence does not support such a simple relationship.

So a more accurate way to frame ketamine treatment is this: dissociation may occur, sometimes quite noticeably, but the clinical task is to monitor it, manage risk, and judge overall benefit over time. The detached feeling is part of the safety picture, not the treatment goal.